ImmunoGen Announces Preclinical Data Presentations for Two ADCs With Novel IGN Payloads at Upcoming 58th ASH Annual Meeting
November 03 2016 - 09:05AM
Business Wire
Includes Oral Presentation on
CD123-Targeting ADC IMGN632
ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field
of antibody-drug conjugates (ADCs) for the treatment of cancer,
today announced that new preclinical data on the Company’s novel
IGN ADCs, IMGN632 and IMGN779, will be presented at the upcoming
American Society of Hematology (ASH) annual meeting, which is being
held December 3-6, 2016 in San Diego, CA.
IMGN632, a CD123-targeting ADC and IMGN779, a CD33-targeting
ADC, both use ImmunoGen’s new family of indolino-benzodiazepine
cancer-killing agents called IGNs. ImmunoGen designed IGN payloads
to alkylate DNA without crosslinking it. Data being presented at
ASH will demonstrate that DNA-alkylating IGNs are ultra-potent, yet
provide increased tolerability compared with DNA crosslinking
versions.
“Accelerating our earlier-stage portfolio with an emphasis on
our IGN ADCs is one of ImmunoGen’s strategic priorities, and we
believe the IMGN632 and IMGN779 preclinical data being presented at
ASH further demonstrate why we are excited about the potential of
these programs,” said Richard Gregory, Ph.D., executive vice
president and chief scientific officer of ImmunoGen.
In an oral presentation, the Company will report preclinical
data demonstrating the activity of IMGN632 in multiple acute
myeloid leukemia (AML) models and patient samples at concentrations
far below levels that affect normal bone marrow cells, suggesting
the potential for efficacy in AML patients in the absence of or
with limited myelosuppression. In a separate poster presentation,
preclinical data for IMGN632 will be reported demonstrating
prolonged survival in AML xenograft models. Preclinical data from a
combination study of IMGN779 with a PARP inhibitor, demonstrating
enhanced activity in several AML models including patient derived
tumor cells and a disseminated AML xenograft model, will also be
presented in an investigator poster presentation.
A Phase 1 trial of IMGN779 as monotherapy in AML is ongoing with
the first clinical data expected to be reported in 2017. ImmunoGen
intends to submit an IND application and initiate clinical testing
of IMGN632 in 2017.
Oral PresentationTitle: “A CD123-Targeting Antibody-Drug
Conjugate (ADC), IMGN632, Designed to Eradicate Acute Myeloid
Leukemia (AML) Cells While Sparing Normal Bone Marrow Cells”
- Oral presentation, session #616:
Monday, December 5, presentation time 11:45am PT. Abstract
#768.
Poster PresentationsTitle: “IMGN632: A CD123-Targeting
Antibody-Drug Conjugate (ADC) with a Novel DNA-Alkylating Payload,
Is Highly Active and Prolongs Survival in Acute Myeloid Leukemia
(AML) Xenograft Models”
- Poster session #616: Sunday, December
4, 6:00-8:00pm PT. Abstract #2832.
Title: “Combining IMGN779, a Novel Anti-CD33 Antibody-Drug
Conjugate (ADC), with the PARP Inhibitor, Olaparib, Results in
Enhanced Anti-Tumor Activity in Preclinical Acute Myeloid Leukemia
(AML) Models”
- Poster session #616: Saturday, December
3, 5:30-7:30pm PT. Abstract #1645.
Data will also be presented on agents which use ImmunoGen’s
maytansinoid ADC technology, including IMGN529 and Biotest’s
indatuximab ravtansine (BT062).
Additional information, including abstracts, can be found at
www.hematology.org.
About ImmunoGenImmunoGen is a clinical-stage
biotechnology company that develops targeted cancer therapeutics
using its proprietary ADC technology. ImmunoGen’s lead product
candidate, mirvetuximab soravtansine, is being advanced to a Phase
3 trial for FRα-positive platinum-resistant ovarian cancer, and is
in Phase 1b/2 testing in combination regimens for
earlier-stage disease. ImmunoGen’s ADC technology is used in
Roche's marketed product, Kadcyla®, in three other clinical-stage
ImmunoGen product candidates, and in programs in development by
partners Amgen, Bayer, Biotest, CytomX, Lilly, Novartis, Sanofi and
Takeda. More information about the Company can be found at
www.immunogen.com.
Kadcyla® is a registered trademark of Genentech, a member of the
Roche Group.
This press release includes forward-looking statements. For
these statements, ImmunoGen claims the protection of the safe
harbor for forward-looking statements provided by the Private
Securities Litigation Reform Act of 1995. It should be noted that
there are risks and uncertainties related to the development of
novel anticancer products, including IMGN632 and IMGN779, including
risks related to preclinical and clinical studies, their timings
and results. A review of these risks can be found in ImmunoGen’s
Annual Report on Form 10-K for the fiscal year ended June 30, 2016
and other reports filed with the Securities and Exchange
Commission.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20161103005287/en/
Investor Contact:ImmunoGen, Inc.Sarah Kiely,
781-895-0600sarah.kiely@immunogen.comorMedia
Contacts:ImmunoGen, Inc.Amy Reilly,
781-895-0138amy.reilly@immunogen.comorFTI Consulting Inc.Robert
Stanislaro, 212-850-5657robert.stanislaro@fticonsulting.com
ImmunoGen (NASDAQ:IMGN)
Historical Stock Chart
From Feb 2024 to Mar 2024
ImmunoGen (NASDAQ:IMGN)
Historical Stock Chart
From Mar 2023 to Mar 2024